Board of Directors Governance Brian McNamee AO MBBS, FTSE Age 67 Chair and Independent Non-executive Director Director of CSL Limited since February 2018 and Chair from October 2018. Paul McKenzie PhD (Chemical Engineering) Age 58 CEO and MD (Non-independent Executive Director) Director of CSL Limited since December 2022, and appointed Chief Executive Officer and Managing Director in March 2023. Megan Clark AC BSc (Hons) PhD Age 66 Independent Non-executive Director Director of CSL Limited since February 2016. Dr McNamee has deep executive experience in the biopharmaceutical industry, with a focus on strategy and creating long-term shareholder value. Dr McNamee was the Chief Executive Officer and Managing Director of CSL from 1990 until 2013. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government’s Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. Other directorships and offices (current and recent): • Chair of Geoff Ogilvy Foundation (since May 2021). Board Committee memberships: • Member of the Innovation and Development Committee; and • Member of the Corporate Governance and Nomination Committee. Dr McKenzie was appointed Chief Executive Officer and Managing Director of CSL Limited on 6 March 2023. Dr McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organisations through compelling growth and transformation. After joining CSL as Chief Operating Officer in June 2019, Dr McKenzie was accountable for optimising CSL’s operations and business growth. He transformed CSL’s global end‑to‑end operations, advanced CSL Seqirus’ differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges while surpassing plasma collection volumes beyond pre-pandemic levels. Prior to joining CSL, Dr McKenzie was executive vice president of Pharmaceutical Operations & Technology at Biogen. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck. Dr McKenzie was elected to the US National Academy of Engineering in 2020. He holds a Bachelor of Science degree in chemical engineering from the University of Pennsylvania and a PhD in chemical engineering from Carnegie Mellon University. Board Committee memberships: • Member of the Innovation and Development Committee. Dr Clark has significant executive and non‑executive experience across a broad range of sectors, including scientific research, health, investment banking and financial services, education and mining. Through her roles, Dr Clark brings a broad strategic perspective and global experience, with a focus on risk and proven health, safety and environment and technology performance. In 2014, Dr Clark was made a Companion of the Order of Australia for eminent service to scientific research and development. Dr Clark was chief executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 until November 2014. Prior to joining CSIRO, she was a director at NM Rothschild and Sons (Australia) and held senior positions at BHP, including vice president (Technology) and vice president (Health, Safety and Environment). Other directorships and offices (current and recent): • Chancellor of Monash University (since July 2024); • Member of MITRE Advisory Board (since December 2022); • Chair of the Australian Space Agency Advisory Board (since January 2021); • Member of the Global Advisory Council of the Bank of America Corporation (since December 2019); • Member of the Australian Advisory Board of the Bank of America (since July 2010); and • Former Director of Rio Tinto Limited and Rio Tinto Plc (from November 2014 to December 2023). Board Committee memberships: • Chair of the Human Resources and Remuneration Committee; • Member of the Corporate Governance and Nomination Committee; and • Member of the Innovation and Development Committee. 58 Limited Annual Report 2023/24
RkJQdWJsaXNoZXIy MjE2NDg3